home / stock / acet / acet quote
Last: | $1.875 |
---|---|
Change Percent: | 1.43% |
Open: | $2.07 |
Close: | $1.875 |
High: | $2.08 |
Low: | $1.865 |
Volume: | 1,352,764 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.875 | $2.07 | $1.875 | $2.08 | $1.865 | 1,352,764 | 04-24-2024 |
$2.1 | $2.14 | $2.1 | $2.25 | $2.07 | 1,147,946 | 04-23-2024 |
$2 | $2 | $2 | $2.045 | $1.955 | 325,351 | 04-22-2024 |
$1.95 | $2.01 | $1.95 | $2.035 | $1.9 | 727,751 | 04-19-2024 |
$2.025 | $2.29 | $2.025 | $2.29 | $2.005 | 930,124 | 04-18-2024 |
$2.27 | $2.22 | $2.27 | $2.35 | $2.215 | 760,776 | 04-17-2024 |
$2.19 | $2.16 | $2.19 | $2.2 | $2.1392 | 171,891 | 04-16-2024 |
$2.2 | $2.16 | $2.2 | $2.26 | $2.13 | 495,246 | 04-15-2024 |
$2.16 | $2.2 | $2.16 | $2.215 | $2.14 | 416,385 | 04-12-2024 |
$2.24 | $2.18 | $2.24 | $2.295 | $2.1301 | 874,525 | 04-11-2024 |
$2.15 | $2.2 | $2.15 | $2.21 | $2.13 | 399,875 | 04-10-2024 |
$2.29 | $2.2 | $2.29 | $2.31 | $2.195 | 486,605 | 04-09-2024 |
$2.18 | $2.22 | $2.18 | $2.26 | $2.1332 | 645,721 | 04-08-2024 |
$2.25 | $2.29 | $2.25 | $2.3 | $2.2192 | 288,769 | 04-05-2024 |
$2.28 | $2.28 | $2.28 | $2.4 | $2.23 | 438,004 | 04-04-2024 |
$2.26 | $2.33 | $2.26 | $2.34 | $2.245 | 456,528 | 04-03-2024 |
$2.36 | $2.35 | $2.36 | $2.37 | $2.29 | 1,535,488 | 04-02-2024 |
$2.4 | $2.35 | $2.4 | $2.43 | $2.28 | 670,271 | 04-01-2024 |
$2.35 | $2.33 | $2.35 | $2.395 | $2.31 | 534,078 | 03-29-2024 |
$2.35 | $2.33 | $2.35 | $2.395 | $2.31 | 534,078 | 03-28-2024 |
News, Short Squeeze, Breakout and More Instantly...
2024-04-23 06:49:48 ET DENVER, Colo., Apr 23, 2024 ( 247marketnews.com )- Adicet Bio, Inc. (Nasdaq: ACET ) stated that a new preclinical data highlighting ADI-270 was selected for an oral presentation at the ASGCT 27th Annual Meeting on May 10, 2024 in the Targeted Gene and Cell The...
Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models ADI-270 demonstrated enhanced functional potency and resilience in tumor microenvironment On track to file an investigational new drug (IND) applicatio...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuit...